Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Nontuberculous Mycobacterial Infection Global Market Report 2025
Download Free Sample Buy Now
Global Nontuberculous Mycobacterial Infection Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Nontuberculous Mycobacterial Infection Global Market Report 2025

By Drug Class (Macrolides, Rifampin, Aminoglycoside, Other Drug Classes), By Route Of Administration (Oral, Parenteral, Other Routes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Nontuberculous Mycobacterial Infection Market Overview

• Nontuberculous Mycobacterial Infection market size has reached to $14.25 billion in 2024

• Expected to grow to $19.37 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%

• Growth Driver: Rising Prevalence Of Copd Fuels Growth In The Nontuberculous Mycobacterial Infection Market

• Market Trend: Adoption Of Innovative Treatment Approvals In The Nontuberculous Mycobacterial Infection Market

• North America was the largest region and fastest growing region.

What Is Covered Under Nontuberculous Mycobacterial Infection Market?

A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than mycobacterium tuberculosis, which is responsible for tuberculosis (TB). The role of nontuberculous mycobacterial (NTM) infections is primarily related to their impact on human health and their interaction with the immune system.

The main classes of drugs for nontuberculous mycobacterial infection are macrolides, rifampin, aminoglycoside and others. Macrolides are a class of antibiotics that are commonly used to treat a variety of bacterial infections. They can be administered through oral, parenteral and other routes, which can be distributed by various channels such as hospital pharmacies, retail pharmacies and online pharmacies.

Nontuberculous Mycobacterial Infection Market Size and growth rate 2025 to 2029: Graph

What Is The Nontuberculous Mycobacterial Infection Market Size 2025 And Growth Rate?

The nontuberculous mycobacterial infection market size has grown strongly in recent years. It will grow from $14.25 billion in 2024 to $14.96 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to improved diagnostics, aging population, cystic fibrosis awareness, immunosuppressive medications.

What Is The Nontuberculous Mycobacterial Infection Market Growth Forecast?

The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few years. It will grow to $19.37 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to antimicrobial drug development, increasing ntm awareness, advances in genetic research, telehealth and remote monitoring. Major trends in the forecast period include personalized treatment, regulatory focus, combination therapies, digital health tools.

The forecast of 6.7% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to clarithromycin-resistant strain diagnostics and inhaled amikacin solutions imported from Germany and India, potentially compromising infection control and increasing pulmonology treatment burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Nontuberculous Mycobacterial Infection Market Segmented?

1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Other Routes

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Macrolides: Azithromycin, Clarithromycin

2) By Rifampin: Rifampin, Rifabutin

3) By Aminoglycoside: Amikacin, Streptomycin

4) By Other Drug Classes: Ethambutol, Clofazimine, Linezolid

What Is Driving The Nontuberculous Mycobacterial Infection Market? Rising Prevalence Of Copd Fuels Growth In The Nontuberculous Mycobacterial Infection Market

The rising prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel the growth of the nontuberculous mycobacterial infection market going forward. Chronic obstructive pulmonary disease (COPD) is a chronic respiratory condition characterized by persistent and often progressive lung airflow limitation. Nontuberculous mycobacterial (NTM) infections in patients with COPD are associated with a more significant decline in forced expiratory volume in one second (FEV1) and an increased exacerbation rate. COPD may weaken the immune system and damage the lung tissue, making IT easier for NTM bacteria to infect the lungs. For instance, in March 2023, according to a report published by The Scottish Public Health Observatory (ScotPHO), a Scotland-based public health body, COPD rates began to climb between 2021 and 2022, with male rates increasing from 83.2 to 97.6 per 100,000 persons while female rates increased from 72.6 to 97.3. Therefore, the rising prevalence of chronic obstructive pulmonary disease (COPD) drives the growth of the nontuberculous mycobacterial infection industry.

What Is Driving The Nontuberculous Mycobacterial Infection Market? Increasing Prevalence Of Infectious Diseases To Drive The Growth Of Nontuberculous Mycobacterial Infection Market

The increasing prevalence of infectious diseases is expected to propel the growth of nontuberculous mycobacterial infection market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms, such as bacteria, viruses, fungi, or parasites, that can be transmitted from one individual to another, leading to a variety of symptoms and health problems. The increasing prevalence of infectious diseases, including conditions that can lead to Nontuberculous Mycobacterial (NTM) infections, can potentially propel the growth of the NTM infection market by raising awareness of these infections, leading to more frequent diagnostic tests and early detection, increased research and development efforts for NTM treatments, and greater demand for therapies targeting NTM pathogens due to heightened healthcare focus on infectious diseases. For instance, in November 2024, according to the United Nations International Children's Emergency Fund (UNICEF), a US-based intergovernmental organization of United Nations agencies, pneumonia was the leading infectious disease causing the death of over 700,000 children annually, equivalent to around 2,000 children per day. Therefore, the increasing prevalence of infectious diseases is driving the growth of nontuberculous mycobacterial infection industry.

Who Are The Major Players In The Global Nontuberculous Mycobacterial Infection Market?

Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.

What Are The Key Trends Of The Global Nontuberculous Mycobacterial Infection Market? Adoption Of Innovative Treatment Approvals In The Nontuberculous Mycobacterial Infection Market

Major companies operating in the nontuberculous mycobacterial infection market adopt new treatment approval practices such as fast track designation for drug approval to sustain their position in the market. Fast Track designation by the FDA is a process designed to expedite the development and review of drugs for serious conditions with unmet medical needs. For instance, in July 2022, the Food and Drug Administration, a U.S.-based federal agency, granted Fast Track Designation for NUZYRA to treat nontuberculous mycobacterial (NTM) lung disease due to Mycobacterium avium complex (MAC). NUZYRA (omadacycline) is a novel broad-spectrum antibiotic designed to combat serious bacterial infections, including those caused by resistant strains. This designation facilitates expedited development and review processes for NUZYRA antibiotic for addressing significant unmet medical needs.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Nontuberculous Mycobacterial Infection Market? Qurient Collaborates With Tb Alliance To Develop Telacebec For Tuberculosis And Ntm Infections

In February 2023, Qurient Co. Ltd., a Korea-based biotech company, partnered with TB Alliance. This partnership aims to develop telacebec, a drug to treat tuberculosis and other nontuberculous mycobacteria (NTM) infections. TB Alliance will be granted the only global license for Telacebec through the agreement. This indicates that the TB Alliance will have the authority to continue working on the medicine and market IT internationally. TB Alliance is a South Africa-based non-profit organization that develops and delivers economic TB medications.

Regional Outlook For The Global Nontuberculous Mycobacterial Infection Market

North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

What Defines the Nontuberculous Mycobacterial Infection Market?

The nontuberculous mycobacterial infection market consists of revenues earned by entities by providing services such as treatment planning, antibiotic therapy, monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The nontuberculous mycobacterial infection market also includes sales of azithromycin, rifampin, ethambutol, streptomycin, medical equipment, pulmonary rehabilitation and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Nontuberculous Mycobacterial Infection Industry?

The nontuberculous mycobacterial infection market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nontuberculous mycobacterial infection industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Nontuberculous Mycobacterial Infection Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $14.96 billion
Revenue Forecast In 2034 $19.37 billion
Growth Rate CAGR of 6.7% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Macrolides: Azithromycin, Clarithromycin
2) By Rifampin: Rifampin, Rifabutin
3) By Aminoglycoside: Amikacin, Streptomycin
4) By Other Drug Classes: Ethambutol, Clofazimine, Linezolid
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics Plc, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Nontuberculous Mycobacterial Infection Market Characteristics

3. Nontuberculous Mycobacterial Infection Market Trends And Strategies

4. Nontuberculous Mycobacterial Infection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Nontuberculous Mycobacterial Infection Growth Analysis And Strategic Analysis Framework

5.1. Global Nontuberculous Mycobacterial Infection PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Nontuberculous Mycobacterial Infection Market Growth Rate Analysis

5.4. Global Nontuberculous Mycobacterial Infection Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Nontuberculous Mycobacterial Infection Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Nontuberculous Mycobacterial Infection Total Addressable Market (TAM)

6. Nontuberculous Mycobacterial Infection Market Segmentation

6.1. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Macrolides

Rifampin

Aminoglycoside

Other Drug Classes

6.2. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Parenteral

Other Routes

6.3. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

6.4. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Macrolides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Azithromycin

Clarithromycin

6.5. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Rifampin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Rifampin

Rifabutin

6.6. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Aminoglycoside, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Amikacin

Streptomycin

6.7. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ethambutol

Clofazimine

Linezolid

7. Nontuberculous Mycobacterial Infection Market Regional And Country Analysis

7.1. Global Nontuberculous Mycobacterial Infection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Nontuberculous Mycobacterial Infection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nontuberculous Mycobacterial Infection Market

8.1. Asia-Pacific Nontuberculous Mycobacterial Infection Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nontuberculous Mycobacterial Infection Market

9.1. China Nontuberculous Mycobacterial Infection Market Overview

9.2. China Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nontuberculous Mycobacterial Infection Market

10.1. India Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nontuberculous Mycobacterial Infection Market

11.1. Japan Nontuberculous Mycobacterial Infection Market Overview

11.2. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nontuberculous Mycobacterial Infection Market

12.1. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nontuberculous Mycobacterial Infection Market

13.1. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nontuberculous Mycobacterial Infection Market

14.1. South Korea Nontuberculous Mycobacterial Infection Market Overview

14.2. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nontuberculous Mycobacterial Infection Market

15.1. Western Europe Nontuberculous Mycobacterial Infection Market Overview

15.2. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nontuberculous Mycobacterial Infection Market

16.1. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nontuberculous Mycobacterial Infection Market

17.1. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nontuberculous Mycobacterial Infection Market

18.1. France Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nontuberculous Mycobacterial Infection Market

19.1. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nontuberculous Mycobacterial Infection Market

20.1. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nontuberculous Mycobacterial Infection Market

21.1. Eastern Europe Nontuberculous Mycobacterial Infection Market Overview

21.2. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nontuberculous Mycobacterial Infection Market

22.1. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nontuberculous Mycobacterial Infection Market

23.1. North America Nontuberculous Mycobacterial Infection Market Overview

23.2. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nontuberculous Mycobacterial Infection Market

24.1. USA Nontuberculous Mycobacterial Infection Market Overview

24.2. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nontuberculous Mycobacterial Infection Market

25.1. Canada Nontuberculous Mycobacterial Infection Market Overview

25.2. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nontuberculous Mycobacterial Infection Market

26.1. South America Nontuberculous Mycobacterial Infection Market Overview

26.2. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nontuberculous Mycobacterial Infection Market

27.1. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nontuberculous Mycobacterial Infection Market

28.1. Middle East Nontuberculous Mycobacterial Infection Market Overview

28.2. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nontuberculous Mycobacterial Infection Market

29.1. Africa Nontuberculous Mycobacterial Infection Market Overview

29.2. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nontuberculous Mycobacterial Infection Market Competitive Landscape And Company Profiles

30.1. Nontuberculous Mycobacterial Infection Market Competitive Landscape

30.2. Nontuberculous Mycobacterial Infection Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.3. F. Hoffman La Roche AG Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Nontuberculous Mycobacterial Infection Market Other Major And Innovative Companies

31.1. Bayer AG

31.2. Novartis AG

31.3. Sanofi S.A.

31.4. Bristol Myers Squibb

31.5. AstraZeneca plc

31.6. Abbott Laboratories

31.7. GlaxoSmithKline plc

31.8. Takeda Pharmaceutical Company

31.9. Eli Lilly and Company

31.10. C.H. Boehringer Sohn AG & Co. KG

31.11. Teva Pharmaceutical Industries Ltd.

31.12. Mylan N.V.

31.13. Astellas Pharma Inc.

31.14. Vertex Pharmaceuticals Inc.

31.15. Sun Pharmaceutical Industries Ltd.

32. Global Nontuberculous Mycobacterial Infection Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nontuberculous Mycobacterial Infection Market

34. Recent Developments In The Nontuberculous Mycobacterial Infection Market

35. Nontuberculous Mycobacterial Infection Market High Potential Countries, Segments and Strategies

35.1 Nontuberculous Mycobacterial Infection Market In 2029 - Countries Offering Most New Opportunities

35.2 Nontuberculous Mycobacterial Infection Market In 2029 - Segments Offering Most New Opportunities

35.3 Nontuberculous Mycobacterial Infection Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Macrolides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Rifampin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Aminoglycoside, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Nontuberculous Mycobacterial Infection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Nontuberculous Mycobacterial Infection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Pfizer Inc. Financial Performance
  • Table 79: Johnson & Johnson Financial Performance
  • Table 80: F. Hoffman La Roche AG Financial Performance
  • Table 81: Merck & Co. Inc. Financial Performance
  • Table 82: AbbVie Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Macrolides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Rifampin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Aminoglycoside, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Nontuberculous Mycobacterial Infection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Nontuberculous Mycobacterial Infection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Pfizer Inc. Financial Performance
  • Figure 79: Johnson & Johnson Financial Performance
  • Figure 80: F. Hoffman La Roche AG Financial Performance
  • Figure 81: Merck & Co. Inc. Financial Performance
  • Figure 82: AbbVie Inc. Financial Performance

Next-Gen Primary Health Care Service : Market Forecast, Transformation, and Long-Term Trajectories

Read More About Next-Gen Primary Health Care Service : Market Forecast, Transformation, and Long-Term Trajectories

Progressive Ataxia And Weakness Disorders Growth Trajectory: Key Forecasts and Strategic Insights

Read More About Progressive Ataxia And Weakness Disorders Growth Trajectory: Key Forecasts and Strategic Insights

Prostate Cancer Nuclear Medicine Diagnostics Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Read More About Prostate Cancer Nuclear Medicine Diagnostics Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Emerging Trends Redefining the Prostate Cancer Nuclear Medicine Diagnostics Market Landscape: Automated Parallel Capillary Electrophoresis Systems Transforming Protein Analysis In The Protein Chip Market

Read More About Emerging Trends Redefining the Prostate Cancer Nuclear Medicine Diagnostics Market Landscape: Automated Parallel Capillary Electrophoresis Systems Transforming Protein Analysis In The Protein Chip Market

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

Read More About A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Read More About A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Read More About A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Read More About A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Nontuberculous Mycobacterial Infection Global Market Report 2025 – By Drug Class (Macrolides, Rifampin, Aminoglycoside, Other Drug Classes), By Route Of Administration (Oral, Parenteral, Other Routes), By Distribution Ch...

View Report

Tuberculosis Diagnostics Global Market Report 2025 – By Test Type (Radiographic Tests, Nucleic Acid Testing, Cytokine Detection Tests, Drug Resistance Tests, Skin Test / Mantoux Test (TST), Blood/Serology Test, Smear Mic...

View Report

Clinical Microbiology Global Market Report 2025 – By Product (Laboratory Instruments, Microbiology Analyzers, Reagents), By Indication (Respiratory Diseases, Sexually Transmitted Diseases, Urinary Tract infections, Perio...

View Report

Rare Disease Diagnostics Global Market Report 2025 – By Test Type (Genetic Test, General Lab Test, Imaging Test), By Technology (Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays), By Sam...

View Report

Interstitial Cystitis Global Market Report 2025 – By Treatment (Medications, Bladder Instillation, Botulinum Toxin A, Nerve Stimulation, Surgery), By Patient Type (Pediatric Patients, Adult Patients), By Drug Type (Over-...

View Report

Bactericide Global Market Report 2025 – By Type (Organic Bactericides, Inorganic Bactericides, Biological Bactericides), By Formulation Type (Liquid Bactericides, Granular Bactericides, Powdered Bactericides), By Crop Ty...

View Report

Bacterial Conjunctivitis Global Market Report 2025 – By Types (Hyperacute Bacterial Conjunctivitis, Acute Bacterial Conjunctivitis, Chronic Bacterial Conjunctivitis), By Drug Class (Antibiotics, Fluoroquinolones, Aminogl...

View Report

Hospital-Acquired Infection Control Global Market Report 2025 – By Product (Sterilizers, Disinfectors, Endoscope Reprocessors, Microbial Testing Instruments, Consumables, Disinfectants, Infection Prevention And Surveilla...

View Report

Frequently Asked Questions

A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than mycobacterium tuberculosis, which is responsible for tuberculosis (TB). The role of nontuberculous mycobacterial (NTM) infections is primarily related to their impact on human health and their interaction with the immune system. For further insights on this market, request a sample here

The market major growth driver - Rising Prevalence Of Copd Fuels Growth In The Nontuberculous Mycobacterial Infection Market. For further insights on this market, request a sample here

The nontuberculous mycobacterial infection market size has grown steadily in recent years. It will grow from $14.25 billion in 2024 to $14.96 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to improved diagnostics, aging population, cystic fibrosis awareness, immunosuppressive medications. The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few years. It will grow to " $19.37 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to antimicrobial drug development, increasing ntm awareness, advances in genetic research, telehealth and remote monitoring. Major trends in the forecast period include personalized treatment, regulatory focus, combination therapies, digital health tools. For further insights on this market, request a sample here

The nontuberculous mycobacterial infectionmarket covered in this report is segmented –
1) By Drug Class: Macrolides; Rifampin; Aminoglycoside; Other Drug Classes
2) By Route Of Administration: Oral; Parenteral; Other Routes
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies Subsegments:
1) By Macrolides: Azithromycin; Clarithromycin
2) By Rifampin: Rifampin; Rifabutin
3) By Aminoglycoside: Amikacin; Streptomycin
4) By Other Drug Classes: Ethambutol; Clofazimine; Linezolid For further insights on this market, request a sample here

North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. For further insights on this market, request a sample here.

Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.. For further insights on this market, request a sample here.

Major trends in this market include Adoption Of Innovative Treatment Approvals In The Nontuberculous Mycobacterial Infection Market. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Nontuberculous Mycobacterial Infection Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon